Piramal Pharma and NP2 to Finish Cyclophosphamide Phase Next Month
Piramal Pharma Solutions and NP2 aim to complete the development phase of the cancer drug cyclophosphamide by next month to tackle global shortages.
In a significant move to bolster the supply of critical oncology medication, Piramal Pharma Solutions (PPS) and its partner NP2 have announced that they are on track to complete the drug development phase for the generic cancer drug cyclophosphamide this October.
The partnership aims to address the precarious supply chain risks and ongoing shortages of this essential medicine, which is vital for treating various types of cancer, including breast cancer and retinoblastoma, a type of eye cancer found in young children.
Tackling Global Cancer Drug Shortages
The need for a more stable supply of cyclophosphamide has become increasingly urgent. Recent data highlights a concerning landscape in oncology medicine availability:
- Widespread Shortages: A National Comprehensive Cancer Network (NCCN) survey revealed that 100% of surveyed member institutions are facing shortages of at least one anti-cancer agent.
- Concentrated Supply: Currently, the top two overseas manufacturers control 92% of U.S. sales for cyclophosphamide, with one single provider managing nearly 70% of the 200 mg ready-to-use solution market.
- International Scarcity: The drug is already facing supply constraints in the European Union and Canada.
By conducting development and manufacturing at Piramal's sterile injectable facility in Lexington, Kentucky, the PPS-NP2 collaboration seeks to shorten the supply chain and ensure that the medicine is produced domestically within the United States.
Strengthening Domestic Manufacturing Capacity
The Lexington site is currently undergoing a massive $85 million expansion designed to boost manufacturing capacity for critical drugs like cyclophosphamide. This investment is a cornerstone of the effort to build a more resilient supply chain.
"Advancing to the manufacturing stage is an exciting next step in NP2's mission to manufacture a steady supply of the life-saving cancer-fighting medicine cyclophosphamide right here in the United States," stated Telly Athanasopoulos, NP2's Head of Manufacturing. He noted that the move provides much-needed peace of mind for both doctors and patients regarding drug availability and price stability.
A Systemic Solution for Patients
Terri Miller, Executive Director of NP2, emphasized that the current crisis is not a failure of science, but a failure of the existing system. She pointed out that the heavy consolidation of manufacturing capacity overseas creates significant anxiety for those battling diseases like leukemia and lymphoma.
"A reliable U.S.-made supply of cyclophosphamide—a mainstay cancer-fighting medicine—does not exist today. NP2 is building it," Miller said. She added that the ultimate goal is to allow patients to focus entirely on fighting their cancer rather than worrying about whether their life-saving medication will be available when they need it.
Peter DeYoung, CEO of Piramal Global Pharma, echoed this sentiment, stating that the partnership is a vital initiative to strengthen the supply of essential oncology medicines and support reliable access to therapy through a more robust domestic infrastructure.